Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did a big update to the iBox. I updated the investment thesis section and added some product pictures.
Mike
RBC Life Sciences Supports Clean Energy by Purchasing Renewable Energy Credits to
Offset 100 Percent of Its Electricity Usage
IRVING, Texas, Jan 12, 2009 /PRNewswire-FirstCall via COMTEX/ -- RBC Life
Sciences (RBCL), a global provider of proprietary nutritional supplements, wound
care and pain management products, is offsetting 100 percent of its electricity
usage for two years as part of a company-wide green initiative.
RBC Life Sciences is purchasing 2,561,550 kilowatt hours of renewable energy
credits, which will help to avoid more than 3.4 million pounds of carbon dioxide
pollution. Over a two-year span, this commitment has an impact comparable to
planting more than 14,000 mature trees and avoiding the pollution associated with
driving 3.4 million miles in an average car.
RBC Life Sciences has also embarked on other energy-saving initiatives. The
company uses recycled paper as cushioning in product shipments, new printer ink
technology that will eliminate hundreds of pounds of used printer cartridges and
special lighting and printing technologies that drastically reduce energy
consumption.
"RBC Life Sciences' commitment to sustainable energy meshes well with the
company's focus on providing nutritional supplements and skin care products that
highlight natural ingredients," said company President and CEO John W. Price.
"This company-wide commitment to reduce our carbon footprint is part of a larger
company effort to promote clean energy projects and help America become less
dependent on fossil fuels."
RBC Life Sciences is purchasing the renewable energy credits from Renewable
Choice Energy, a Colorado-based company that works with the nation's alternative
energy sector. Every credit purchased helps fund new renewable energy projects,
such as wind farms.
About RBC Life SciencesRBC Life Sciences develops, manufactures and markets
high-quality nutritional supplements and personal care products to a growing
population of consumers seeking wellness and a healthy lifestyle. Under its MPM
Medical Inc. brand, RBC Life Sciences also develops and markets to health care
professionals in the United States proprietary prescription and nonprescription
products for advanced wound care and pain management. All products are tested for
quality assurance in-house, and by outside independent laboratories, to comply
with regulations in the U.S. and in more than thirty countries in which the
products are distributed. For more information, visit the Company's Web site at
http://www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be
forward-looking. Actual events will be dependent upon a number of factors and
risks including, but not limited to, changes in plans by the Company's
management, delays or problems in production, changes in the regulatory process,
changes in market trends, and a number of other factors and risks described from
time to time in the Company's filings with the Securities and Exchange
Commission.
SOURCE RBC Life Sciences
http://www.rbclifesciences.com
Copyright (C) 2009 PR Newswire. All rights reserved
RBC Life Sciences Promotes Industry Veteran John W. Price to CEO; Company Founder, Clinton Howard, Will Remain Chairman of the Board
Monday January 5, 7:00 am ET
IRVING, Texas, Jan. 5 /PRNewswire-FirstCall/ -- RBC Life Sciences (OTC Bulletin Board: RBCL - News) announced today that it has elected current president, John W. Price, to CEO effective January 1, 2009. Company founder, Clinton Howard, who is currently CEO, will remain as chairman of the board of directors.
The promotion comes at a time when RBC Life Sciences, a global provider of proprietary nutritional supplements, wound care and pain management products, is growing domestically and internationally. The company announced recently that third quarter net sales and earnings both increased 26 percent over the same period last year.
"John possesses the perfect skill set to take RBC Life Sciences to the next level," said Mr. Howard, who founded the company in 1991. "He has the vision, leadership and focus needed to pilot a multinational company to the forefront of its industry."
A retired U.S. naval commander, Price was named president of RBC Life Sciences in December 2007. He will retain the position of president after being promoted to CEO January 1. Prior to joining the company, he served as a senior executive for two major companies that market nutritional supplements domestically and internationally. Price also led a successful management consulting company and spent 17 years as a senior officer of pharmaceutical giant Eli Lilly.
"It's an exciting time for RBC Life Sciences," said Price, a triathlon athlete who practices the healthy nutrition and exercise promoted by the company. "We're redoubling our efforts to grow our North American market while undertaking aggressive international expansion. We have a healthy balance sheet driven by sales of nutritional supplements and medical device products that are backed by science and are receiving increasing accolades within their industries."
The company's medical devices brand, MPM Medical Inc., is growing strongly. Sales of MPM's evidence-based prescription and non-prescription wound care and pain management products increased 42 percent during the third quarter of 2008 compared to the same period last year. The Kroger Co. began carrying some of MPM's products in its 1,900 pharmacies nationwide in March 2008. The public may purchase MPM products directly from the company's Web site: www.mpmmedicalinc.com.
In his previous company, Carrington Labs, Mr. Howard assembled the team of scientists responsible for discovering the most-active compound responsible for the renowned health-giving benefits of the aloe vera plant. He leaves a 50-year legacy that has touched lives around the world. Some of his many career milestones include serving as founding president of the hospital now named Baylor Medical Center at Irving, creating the nation's first network of clinical laboratories in the 1960s and founding RBC Life Sciences, a company whose products are receiving worldwide critical acclaim.
"It's been a humbling journey," said Mr. Howard. "An impetus for much of what I've tried to accomplish in my personal and business life follows the adage: 'It doesn't have to be this way.' You don't have to settle for status quo when it comes to helping others."
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Source: RBC Life Sciences
The January Effect After Really Bad Years In Stocks
12.11.2008
"What about investing in small cap stocks in January following a terrible year in stocks? In this case I examined all of the years back to 1927, took the 10 worst years in stocks, and examined how small caps (bottom 20% by market cap) performed the following January. The average performance for the S&P 500 the year prior was -21.22%.
The results? An astonishing average performance of 18.17% per January with the worst year being a positive 2.2% (2003). Adding in cash returns the following 12 months and you have returns over 20%."
http://worldbeta.blogspot.com/2008/12/january-effect-after-really-bad-years.html
Patients Experienced Nearly a 70% Reduction in Pain When Using MPM Medical's Regenecare Wound Care Gel
Monday November 17, 8:21 am ET
Regenecare Continues to Garner Clinical Acclaim
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences (OTCBB:RBCL - News) — A recent clinical study found that patients experienced nearly a 70% reduction in pain when MPM Medical Inc.’s Regenecare HA® hydrogel was used prior to and during the changing of their wound dressings.
The finding comes at a time when a cross-section of American thought leaders are calling the lack of proper pain management a national healthcare crisis. In answer, members of Congress have united to sponsor the National Pain Care Policy Act of 2008 (H.R. 2994) to improve “pain research, education, access and care.”
“Pain management is at a critical juncture in American health care,” said MPM Medical President Paul Miller. “Many people are suffering needlessly. This recent study is just one of many over the last several years showing that Regenecare and other MPM products are unique within the field of wound care and pain management.”
Regenecare is one of many proprietary wound care and pain management products offered by MPM Medical, a subsidiary of RBC Life Sciences, Inc.— a leading provider of evidence-based nutritional supplements and personal care products. The Kroger Co. began carrying Regenecare HA in its 1,900 pharmacies earlier this year. Consumers may also purchase MPM’s products from the company Web site, http://www.mpmmedicalinc.com.
Presented in October at the Clinical Symposium on Advances in Skin and Wound Care in Las Vegas, the study evaluated 47 patients suffering from deep, painful wounds, including various kinds of ulcers and surgical and trauma wounds.
Given that patients consistently rate the changing of wound dressings as the time of greatest pain, the study focused on this aspect of pain management. The 47 patients received the first dressing change without the use of Regenecare or any type of pain medication. During subsequent dressing changes, they received Regenecare gel.
The study concluded that Regenecare reduced the pain patients suffered during wound dressing changes by a “very highly significant amount.” Based on a 10-level scale, patient-reported pain averaged 6.8 before using Regenecare. When the Regenecare gel was used prior to and after dressing changes, patient-reported pain averaged 2.3—nearly a 70% reduction.
The study attributed the pain-reducing benefits to Regenecare’s 2% lidocaine-HCI, its high-molecular-weight aloe vera extract and marine collagen—a natural humectant and moisturizer that has been shown to enhance wound repair mechanisms within the epidermis.
Another study presented this year at the 33rd Annual Congress of the Oncology Nursing Society reported similarly impressive results. More than 85 percent of the oncology patients participating in the trial said Regenecare dramatically reduced itching and pain and promoted healing of the often-severe skin rashes associated with anti-cancer drugs.
“In recent years, there has been growing evidence that the experience of living with a chronic wound has a huge impact on a patient’s quality of life,” the study’s principal researcher, Brad Pontani, M.D., medical director of the Southeast Texas Hyperbaric Medicine Center, said, citing an article in the International Wound Journal. “The significance of pain in wound healing is much neglected because of biases against pain management in general, a lack of knowledge in available analgesics and difficulties associated with pain measurement.”
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Contact:
RBC Life Sciences
Alan Van Zelfden, 972-893-4050
alan.vanzelfden@rbclifesciences.com
or
Ann Billings, 972-893-4000
ann.billings@rbclifesciences.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences
[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: STX, N, PAG, KOW, VSPC, RBCL, APNX, UTRK, TNOG, EMGE, HRAL
Friday November 14, 7:00 am ET
NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Wall St. Network's 3-Minute Press Show is a daily program hosted by WSN reporter Tracee Tolentino that features in-depth interviews with public company executives on their company and most recent press releases.
The show is designed to provide viewers with insight into a company's latest news, and its impact on the company's growth.
Shows air Monday through Friday at:
http://tv.wallst.net/3-min-press/3-min-press.php
The following executives were interviewed on today's show:
1. Valerie Fawzi, Senior Director of Product Marketing for i365, a Seagate Technology (Nasdaq: STX - News) company. To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Valerie-Fawzi/340/1344/
Ask Valerie Fawzi a question, post a comment on her profile page, and join her financial social network today at:
http://my.wallst.net/Valerie-Fawzi
2. Mini Peiris, VP of Product Marketing for NetSuite, Inc. (NYSE: N - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Mini-Peiris/340/1347/
Ask Mini Peiris a question, post a comment on her profile page, and join her financial social network today at:
http://my.wallst.net/Mini-Peiris
3. Ken Kettenbeil, Director of Communications for smart USA Distributor LLC, a subsidiary of Penske Automotive Group, Inc. (NYSE: PAG - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Ken-Kettenbeil/340/1338/
Ask Ken Kettenbeil a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Ken-Kettenbeil
4. Stephen Lerch, Chief Revenue Officer for Kowabunga!, Inc. (Amex: KOW - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Stephen-Lerch/340/1343/
Ask Stephen Lerch a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Stephen-Lerch
5. Carl Kukkonen, CEO of VIASPACE, Inc. (OTC Bulletin Board: VSPC - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Carl-Kukkonen/340/1339/
Ask Carl Kukkonen a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Carl-Kukkonen
6. John Price, President of RBC Life Sciences, Inc. (OTC Bulletin Board: RBCL - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/John-Price/340/1342/
Ask John Price a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/John-Price
7. Don Squire, Chief Financial Officer for Alpine Air Express, Inc. (OTC Bulletin Board: APNX - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Don-Squire/340/1348/
Ask Don Squire a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Don-Squire
8. Keith Tench, President of Universal Tracking Solutions, Inc. (OTC Bulletin Board: UTRK - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Keith-Tench/340/1345/
Ask Keith Tench a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Keith-Tench
9. Brandon Toth, President of Titan Oil and Gas, Inc. (Pink Sheets: TNOG - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Brandon-Toth/340/1346/
Ask Brandon Toth a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Brandon-Toth
10. John Cappello, President of Emergent Health Corp. (Pink Sheets: EMGE - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/John-Cappello/340/1341/
Ask John Cappello a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/John-Cappello
11. Robert Oswald, President of HearAtLast Holdings, Inc. (Pink Sheets: HRAL - News). To view this clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Robert-Oswald/340/1340/
Ask Robert Oswald a question, post a comment on his profile page, and join his financial social network today at:
http://my.wallst.net/Robert-Oswald
About WallStreet Direct, Inc.
WallStreet Direct, Inc. operates Wall St. Network (http://www.wallst.net), a leading source of up-to-the-minute business news, social networking applications, comprehensive financial tools and original multimedia content for the investment community. In addition to WSN, WallStreet Direct owns and operates WallStRadio (http://radio.wallst.net), an online hub for business podcasts from well-known business news personalities and publishers, and WallStTV (http://tv.wallst.net), a hub for business and finance video content. We have received eight hundred forty dollars from VIASPACE, Inc. for press release dissemination services. To read our full disclaimer, and for a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.php.
Contact:
WallStreet Direct, Inc.
800-4-WALLST
SOURCE WallStreet Direct, Inc.; Seagate Technology; NetSuite, Inc.; Penske
Automotive Group, Inc.; Kowabunga!, Inc.; VIASPACE, Inc.; RBC Life
Sciences, Inc.; Alpine Air Express, Inc.; Universal Tracking
Solutions, Inc.; Titan Oil and Gas, Inc.; Emergent Health Corp.;
HearAtLast Holdings, Inc.
--------------------------------------------------------------------------------
Source: WallStreet Direct, Inc.; Seagate Technology; NetSuite, Inc.; Penske
Looks like ping pong between two people with really small balls.
Here is the updated backlog information for CCI their principal licensee. Backlog is at the second highest level ever indicating increased demand. The backlog in Q2 was abnormally high due to a shipping problem that pushed some sales from Q2 into Q3. Q4 should be a very nice quarter as projected by the backlog. The EPS in Q4'07 was only $0.008 so Q4'08 EPS will really shine.
Quarter Backlog
Q3'08 $8,698,000
Q2'08 $11,200,000
Q1'08 $6,081,000
Q4'07 $5,778,000
Q3'07 $5,828,000
Q2'07 $6,369,000
Q1'07 $5,343,000
Q4'06 $3,374,000
Q3'06 $2,718,000
Q2'06 $3,469,000
Q1'06 $3,091,000
Q4'05 $2,436,000
Major Painting going on now. Trades at $0.40 Now it Trades at $0.60 with all of 500 shares going through, you have to love these spreads, they have gone ridiculous. LOL.
I no it is probably not the same seller, I was just trying to joke about the liquidity of some of these microcaps in a very sarcastic manner. and I understand about the backlog, that is why I said I expected the backlog to drop, as far as I'm concerned I totally agree that RBCL.OB is a steal at current Prices. Just my opinion.
I don't think you can say a 5K sell is the same as the seller that sold several 10s of thousands recently. On Monday 64,700 shares traded hands. A 5K share sale is only $2.5K which is nothing. Besides, the price is back up to $0.589.
On the backlog.....There were two reasons that backlog was up a huge amount last quarter. One reason was that CCI sales are increasing. The other reason was that they had a shipping delay problem which pushed some sales from Q2 to Q3. With the second strongest backlog ever after resolution of this shipping problem it is clear that CCI demand is continuing to increase. IMO RBCL is a steal at these prices.
Mike
Looks like today's seller was from Ameriturd.
So much for that seller being wiped out. He came back with a huge 5k shares and knocked the stock down 23%. What is even better is the bid is now down to $0.36 apparently all the buyers disappeared. One thing I wasn't crazy about was the Backlog was down sequentially, although I expected that. Still a strong 8.7 Million though, which I think is the second highest backlog we have seen. So Overall still pretty happy and the share price is outrageously cheap at this point. Just my opinion.
Clinical Trial Highlights Supplement's Unique Hydration Benefits
Wednesday November 12, 8:34 am ET
RBC Life Sciences' Nutritional Supplement, Microhydrin, Increased Athletes' Hydration Levels Significantly During Intense Exercise
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences (OTCBB: RBCL - News) — A university clinical trial has shown that athletes dramatically increased their hydration values during intense exercise after consuming RBC Life Sciences’ Microhydrin®—the nutrition industry’s most uniquely formulated super antioxidant.
Exercise physiologists say that hydration is a critical aspect in health and sports competition. Athletes are encouraged to compete while well hydrated to maximize hormonal, mechanical and metabolic benefits.
Results of the trial conducted by the University of Oklahoma Department of Health and Exercise Science were presented in October at the American College of Sports Medicine.
As part of the trial, 15 cyclists participated in an exhaustive uphill bicycle climb in the laboratory. The cyclists consumed four Microhydrin capsules daily for one week prior to the trial. Thirty minutes before the climb, participants consumed three of the super antioxidant capsules with 16 ounces of water. After finishing the trial, the cyclists consumed one Microhydrin capsule with eight ounces of water.
The athletes’ total body water and intracellular water “increased at a significantly greater rate” upon consuming the Microhydrin super antioxidant than when consuming the same amount of water alone, according to the study.
“We have numerous testimonies over the years—from weekend warriors to master marathon runner Andrey Kuznetsov—that Microhydrin plays a critical role in their exercise and competition regimens,” said RBC Life Sciences founder and CEO, Clinton Howard. “Based on the significant increase in intracellular water as measured by this study, it’s evident that Microhydrin has metabolically important functions at the cellular level.”
Numerous clinical trials and studies over the last 10 years indicate that Microhydrin has myriad benefits, including increasing hydration, lowering lactic acid levels in blood during strenuous exercise and protecting against oxidative stress.*
Microhydrin’s superior hydrating and antioxidant benefits are derived from the synergy among the ingredients in its unique formulation, which includes naturally occurring food-grade silica, potassium carbonate, magnesium sulfate and fatty acids. While a previous study had shown that Microhydrin enhanced hydration during daily activity, this new study indicates it also increases hydration during exhaustive exercise.
In 1991, Canadian physician Denis Brown tried to climb 28,750-foot Mt. Everest without supplemental oxygen. In 1994, he was able to reach 26,000 feet. Five years later, at age 47, Brown added Microhydrin to his regimen, hoping to reduce the build-up of free radicals and lactic acid. He succeeded in reaching the South Summit peak without supplemental oxygen.
Marathon runner Andrey Kuznetsov ran the Brazil Marathon in January 1997, at age 39, in 2 hr., 17 min. and 52 sec. In 1999, after adding Microhydrin to his daily regimen, he won the Masters Division of the Boston Marathon in 2 hr., 14 min. and 20 sec., despite a pervasive heat that knocked many runners out of the race. After the race in the recovery room, Kuznetsov was standing, appearing relaxed, while others were collapsed on cots and being treated for hyperthermia and vomiting, said the runner’s nutritional advisor, Leonard Smith, M.D.
* These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at http://www.rbclifesciences.com/.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Contact:
RBC Life Sciences
Alan Van Zelfden, 972-893-4050
alan.vanzelfden@rbclifesciences.com
or
RBC Life Sciences
Ann Billings, 972-893-4000
ann.billings@rbclifesciences.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences
OT Hweb
TTIL with crappy #'s! You think they can make a profit next year?
It was nice to close at $0.65. It looked like a major seller or two were cleared out today.
Mike
.60 X .65 looking nice!
There has been nice RBCL volume today. So far there has been 52.7K shares that have traded hands.
Mike
RBC Life Sciences' Sales and Earnings Increased 26 Percent During the Third Quarter of 2008
Monday November 10, 8:35 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences Inc. (OTCBB: RBCL - News), a provider of proprietary nutritional supplements, wound care and pain management products, today reported net sales of $9.93 million for the quarter ended September 30, 2008 — a 26 percent increase over net sales of $7.86 million for the same period last year.
RBC Life Sciences recorded net earnings of $846,000, or $0.04 per share, during the third quarter of 2008 — a 26 percent increase over net earnings of $672,000, or $0.03 per share, during the third quarter of 2007.
“International licensee sales for the quarter increased 36 percent over sales in the same quarter last year,” said RBC Life Sciences founder and CEO, Clinton Howard. “Considering current economic conditions, the company is fortunate to have ample working capital to finance this rate of growth. The company also has a healthy balance sheet whose only debt consists of the company’s mortgage on its headquarters facility.”
The company’s MPM Medical Inc. brand of medical devices also continued to grow strongly. Sales of MPM’s evidence-based prescription and non-prescription wound care and pain management products increased 42 percent over the same period last year.
The growth comes at a time when the company has refocused efforts to grow its U.S. and Canadian markets while embarking on aggressive international expansion.
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange.
RBC Life Sciences, Inc.
Summary Results of Operations
(in thousands, except per share data)
(unaudited)
Quarters Ended September 30, 2008 2007
Net sales $ 9,925 $ 7,857
Gross profit 4,710 4,155
Operating profit 1,387 1,178
Earnings before income taxes 1,344 1,127
Provision for income taxes 498 455
Net earnings 846 672
Earnings per share
Basic $ 0.04 $ 0.03
Diluted $ 0.04 $ 0.03
Weighted average shares outstanding – basic 21,587 20,425
Weighted average shares outstanding – diluted 22,906 22,803
Nine Months Ended September 30, 2008 2007
Net sales $ 23,160 $ 20,397
Gross profit 11,909 11,253
Operating profit 2,499 2,636
Earnings before income taxes 2,367 2,472
Provision for income taxes 890 965
Net earnings 1,477 1,507
Earnings per share
Basic $ 0.07 $ 0.07
Diluted $ 0.06 $ 0.07
Weighted average shares outstanding – basic 21,315 20,293
Weighted average shares outstanding – diluted 22,923 22,440
RBC Life Sciences, Inc.
Condensed Balance Sheets
(in thousands)
(unaudited)
September 30, December 31,
2008 2007
Assets
Cash and cash equivalents $ 7,130 $ 6,369
Inventories 4,885 4,725
Other current assets 1,620 1,334
Total current assets 13,635 12,428
Other assets 6,777 6,730
Total assets $ 20,412 $ 19,158
Liabilities and shareholders’ equity
Accounts payable and accrued liabilities $ 3,397 $ 4,431
Deferred revenue 5,077 4,323
Other current liabilities 141 136
Total current liabilities 8,615 8,890
Other liabilities 2,529 2,690
Shareholders’ equity 9,268 7,578
Total liabilities and shareholders’ equity $ 20,412 $ 19,158
Awesome! Just as I thought!
Mike
RBCL earnings out....earned .04 a share.....BRIG
I'm planning for the future. I think there will be a lot more posts when earnings come out.
Mike
Yeah, what a busy board you have here. Thank God you have help to sort through all these posts.
Welcome Rawnoc as an assistant moderator.
Mike
RBC Life Sciences Wins Top Award for its Antioxidant Product, OliViva, While Competing against a Field of National Brands
Friday November 7, 9:08 am ET
IRVING, Texas--(BUSINESS WIRE)--Some of the package industry’s leading experts have awarded RBC Life Sciences (OTCBB: RBCL - News) a first-place award for the visually appealing design of the nutritional supplements company’s newest antioxidant product, OliViva™.
packagePrinting magazine annually assembles a team of the industry’s leading experts to judge designs submitted by some of the nation’s largest brand names. The panel granted its top award for excellence this year to the label design for OliViva. It found the design to be visually appealing, that it served its intended purpose and that it exhibited superior printing technique. Previous winners have included Bacardi, Victoria’s Secret and Gillette.
“We’re honored that these prestigious industry experts recognized the beauty of OliViva’s branding,” RBC Life Sciences President John W. Price said of the drink made from freshly harvested olive leaves and other natural botanicals. “And rest assured, OliViva tastes as good as its packaging looks.”
OliViva comes in a 30-ounce glossy black bottle accented with a visually appealing neon-green accent stripe and an elegantly designed brand name. A dove was added to the design to promote the historical significance of a product based on olive leaf extract. The synergy of the imagery creates a striking package that draws the eye to the brand name.
The antioxidant drink’s branding also recently won a silver-place award presented by the Flexographic Technical Association as part of its Excellence in Flexography Awards Competition.
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Contact:
RBC Life Sciences
Alan Van Zelfden, 972-893-4050
alan.vanzelfden@rbclifesciences.com
or
Ann Billings, 972-893-4000
ann.billings@rbclifesciences.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences
Lots of shares available at .50--someone is coughing them up.
Saw the ask briefly jump to .60, back down now.
Small blocks though so I am guessing not a fund ala EGMI?
I think RBCL will easily beat their Q3'07 numbers which had an excellent EPS of $0.029/share. I'm looking for EPS of at least $0.04/share and possibly as much as $0.07. Below is a post I made recently of my RBCL investment thesis which is mostly taken from the iBox:
---------
RBCL IMO will be a multibagger like ZYXI within the next year and will likely have a 50-200% move upon releasing their blockbuster Q3 earnings announcement to come out by mid November. RBCL is a maker of nutritional and medical products and thus is recession resistant. My estimate is that they will make at least $0.04/share in Q3 and possibly as much as $0.07/share! Those will be awesome earnings for a company that last traded at $0.50. Here are some more reasons why I think they are poised to move significantly higher:
1. Huge Backlog Increase - Backlog jumped from $6.1M to $11.2M for their CCI account in the most recent quarter which is unprecedented!. To put this in perspective their revenue last quarter was $6.9M. Also, the backlog only represents a portion of their sales going forward. They have GM of 53.4% so additional sales drop rapidly to the bottom line.
2. Rapidly Growing Medical Sales - Medical sales jumped 40% year-over-year and looks like it will continue. At the end of March they announced an expansion of their medical segment into Latin America. They also announce in February that they would begin selling their products in Kroger. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=28065107 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26926765
3. Q2 EPS One-Time Items - Q2 EPS was impacted by some one-time items. They incurred expenses for an event to train/motivate their sales associates and also had expenses for renovations on their headquarters' building. They didn't quantify the costs for these one time items but certainly EPS would have been higher without them. I suspect the EPS impact was on the order of $0.008/share. Also they had some shipping delays that impacted Q2. Without these one-time items the Q2 report would have been much better.
4. Strong Balance Sheet - RBCL has a book value of $0.39 and only a tiny amount of debt. That puts them in a strong position financially to grow.
More DD on my largest holding can be found here:
http://investorshub.advfn.com/boards/board.aspx?board_id=9877
Mike
I added some RBCL today as earnings could be out as early as next week. Finally in a buying mood again after seeing MALL, ALIF, EGMI, etc. the last 2 days...and being reminded that stocks can actually go up!
As for RBCL, the huge backlog increase should bode well for Q3 results. I'm hoping for a .03-.04 quarter. Only bad thing is they're going up against an extremely tough comp. So I'm not sure how much attention we'll get as the year-over-year increases may be flat. That said, the stock is way too cheap here with a low P/E in a defensive sector, plus a strong balance sheet with nearly half of the market cap in cash.
Added to RBCL.OB at $0.50.
Nice buying going on here! 26.5K picked off at the ask!
Mike
I picked up more shares today at $0.48. IMO RBCL is a steal at these levels.
Mike
RBC Life Sciences Embarks on its Nationwide "Bright Future" Tour to Introduce its New Nutritional Products and Financial Opportunities
Tuesday October 14, 8:49 am ET
30-City Tour Highlights Health, Nutrition and Financial Freedom
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences (OTCBB: RBCL - News), a leading global provider of evidence-based nutritional supplements and personal care products, launched its “Bright Future” tour in Los Angeles last week to introduce the company’s new products and business opportunities to main street America.
“The Bright Future tour comes at a time when people across the country increasingly are concerned about escalating healthcare costs and about an economy that is placing a strain on their personal finances,” said RBC Life Sciences President John Price. “Many of these people have refocused their attention on health, nutrition and exploring opportunities to supplement their incomes. We can help them achieve their goals.”
Company representatives launched the tour in Los Angeles on October 10 and 11. The tour will continue in Alexandria, Minnesota, October 24 and 25, eventually reaching 30 cities in 16 states.
RBC Life Sciences stands alone in its legacy of providing the highest-quality nutritional and personal care products based on clinical science, proprietary technologies and the most-efficacious ingredients. The company doesn’t use the word ‘pioneer’ lightly. For example, the company’s founder, Clinton Howard, was instrumental in isolating the long-chain polysaccharide in aloe vera that is responsible for the plant’s legendary healing benefits.
RBC Life Sciences is “growing at a rapid clip,” according to a recent article on the company by AMR Research, a national business analysis firm. The company is comprised of a medical products company, MPM Medical Inc., and a nutritional supplements provider, RBC Life Sciences. MPM recently witnessed an amazing 32% growth, quarter over quarter, while the nutritional supplements company experienced 14% growth at a time when many of its competitors were stagnant or declining.
“Many Americans are facing tough times,” Price said. “News reports say an increasing number of people are looking to supplement their incomes through direct marketing, which typically sees good growth during economic downturns. RBC Life Sciences believes it has the most attractive combination of nutritional supplements and compensation plan in the industry.”
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange.
Contact:
Van Zelfden Communications
Alan Van Zelfden, 469-964-0216
alan.vanzelfden@rbclifesciences.com
or
RBC Life Sciences
Steve Brown, 972-893-4000
steve.brown@rbclifesciences.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences
RBCL adds a new Director
(PR Wires) PRW: RBC Life Sciences Names Veteran Strategic Growth Leader, Rob
rt Kaiser, to the Company's Board of Directors
PRW: RBC Life Sciences Names Veteran Strategic Growth Leader, Robert Kaiser, to
he Company's Board of Directors
IRVING, Texas--(BUSINESS WIRE)--September 23, 2008--
RBC Life Sciences (OTCBB: RBCL), a leading global provider of evidence-based
nutritional supplements and personal care products, has named strategic
growth veteran Robert A. Kaiser to its board of directors.
Kaiser brings more than three decades of executive-level leadership to the
board at a time when RBC Life Sciences is focusing on aggressive domestic
and international expansion. Comprised of an advanced wound care and pain
management products subsidiary and a nutritional supplements subsidiary, RBC
Life Sciences grew nearly 25 percent in 2007.
"Robert has an impressive entrepreneurial background and strategic
experience in profit and revenue expansion and shareholder development that
will serve the company as it positions itself moving forward," said RBC Life
Sciences President John Price. "Robert's expertise will be invaluable as we
redouble growth efforts within the United States and abroad."
Kaiser is chairman and CEO of CLST Holdings, the public company remaining
from the 2007 sale of Cellstar Inc., an international logistics and
distribution firm serving the communications industry. As Cellstar's
chairman and CEO, Kaiser raised the company's market capitalization by
securing new funding sources, developing new product lines and entering new
markets.
"RBC Life Sciences has a compelling story of helping people globally improve
quality of life," Kaiser said. "Its nutritional supplements subsidiary of
the same name offers one of the most-respected array of products in the
industry. Meanwhile, its wound care and pain management subsidiary -- MPM
Medical Inc. -- is continuing to gain praise for its one-of-a-kind product
offering. I am proud to join RBC's board to help it become the household
name that it deserves."
Kaiser previously was CEO of Mobile Star, CEO and CFO of Skytel/Worldcom
from 1996 to 2001, CFO of Cingular/Southwestern Bell Mobile Systems from
1986 to 1996 and CFO of LTV Energy from 1976 to 1985.
RBC Life Sciences is a pioneer in the truest definition of the word. The
company's founder, CEO Clinton Howard, made history during the early 1980s
when he organized a team of scientists to unlock the age-old mystery behind
the health-giving properties of the aloe vera plant.
For centuries, scribes--everyone from Old Testament authors and Egyptian
pharaohs to Aristotle and Alexander the Great--have sung the praises of the
unassuming plant, yet none were able to pinpoint why it was beneficial to
health.
Howard's team cracked the code--and entered the annals of medical
history--when it isolated the active ingredient, a long-chain polysaccharide
found in the inner leaf gel of the plant. Howard incorporated his findings
into many of the nutritional supplements and personal care products offered
by RBC Life Sciences. Meanwhile, MPM Medical incorporated the findings into
its array of wound care and pain management products. MPM Medical joined RBC
Life Sciences in 1991.
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high quality
nutritional supplements and personal care products to a growing population
of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical
brand, RBC Life Sciences also develops and markets to health care
professionals in the United States proprietary prescription and
nonprescription products for advanced wound care and pain management. All
products are tested for quality assurance in-house, and by outside
independent laboratories, to comply with regulations in the U.S. and in more
than thirty countries in which the products are distributed. For more
information, visit the Company's Web site at
http://www.rbclifesciences.com/.
The statements above, other than statements of historical fact, may be
forward-looking. Actual events will be dependent upon a number of factors
and risks including, but not limited to, changes in plans by the Company's
management, delays or problems in production, changes in the regulatory
process, changes in market trends, and a number of other factors and risks
described from time to time in the Company's filings with the Securities and
Exchange Commission.
CONTACT: Van Zelfden Communications
Alan Van Zelfden, 469-964-0216
alan.vanzelfden@rbclifesciences.com
or
RBC Life Sciences
Ann Billings, 972-893-4000
ann.billings@rbclifesciences.com
SOURCE: RBC Life Sciences
Copyright Business Wire 2008
(END) Dow Jones Newswires
September 23, 2008 09:17 ET (13:17 GMT)
*** end of story ***
Nice PR just out on RBCL
(BSNS WIRE) RBC Life Sciences President Says Its Nutritional Supplements and
edical Products Companies Are Capitalizing on a Trill
RBC Life Sciences President Says Its Nutritional Supplements and Medical Product
Companies Are Capitalizing on a Trillion-Dollar Industry
IRVING, Texas--(BUSINESS WIRE)----
RBC Life Sciences: (OTCBB: RBCL) -- A national business advisory
firm recently featured RBC Life Sciences, a leading global provider of
evidence-based nutritional supplements and personal care products, in
an interview highlighting the company's growth.
In the interview, AMR Research referred to RBC Life Sciences as "a
small company that has been growing at a rapid clip." In 2007, for
example, RBC Life Sciences grew nearly 25 percent on the back of rapid
domestic and international growth within the company's nutritional
supplements and medical products subsidiaries.
"RBC Life Sciences subsidiaries possess an incredible synergy,"
said RBC Life Sciences President John Price. "On the one hand, MPM
Medical Inc. has a range of wound care and pain management products
that are increasingly gaining accolades within the industry. Many of
these products are aloe-based as are many of the company's nutritional
supplements and personal care products. These companies also share the
distinction of their products being backed by evidence-based studies
and science."
Price said RBC Life Sciences is well-prepared to capitalize on one
of the most momentous changes in the health and wellness industries
globally. Economist Paul Zane Pilzer has predicted that health and
wellness will become the next trillion-dollar industry. With health
care costs increasing beyond the reach of many, people are focusing on
maintaining optimal health, Pilzer said.
"Proper diet is critical for optimal health," Price said. "Few
people, however, have the discipline to maintain such a diet. Even if
they did, many of our foods these days simply don't have the same
levels of important vitamins, minerals and phytonutrients that they
had just a generation ago."
An article in the 2002 Journal of the American Medical Association
said it was "prudent" for American adults to take nutritional
supplements because they were unlikely to receive the vitamins and
minerals their bodies need from diet alone. But not all nutritional
supplements are created equal.
Price said he believes RBC Life Sciences is uniquely situated
because its products are based on validated science and proprietary
technologies. RBC Life Sciences' products are formulated, tested and
ensured for safety in the company's state-of-the-art laboratory. All
ingredients are harvested and manufactured according to national Good
Manufacturing Practices.
RBC Life Sciences is a pioneer in the true definition of the word.
The company's founder, CEO Clinton Howard, made history during the
early 1980s when he organized a team of scientists to unlock the
age-old mystery behind the healing properties of the aloe vera plant.
For centuries, scribes--everyone from Old Testament authors and
Egyptian pharaohs to Aristotle and Alexander the Great--have sung the
praises of the unassuming plant, yet none were able to pinpoint why it
was so beneficial to health.
Howard's team cracked the code when it isolated the active
ingredient--a long-chain polysaccharide found in the inner leaf gel of
the plant. Dubbed 'acemannan,' this glyconutrient holds the key to the
aloe vera's health benefits.
"This dedication to science is the bedrock upon which RBC Life
Sciences is built," Price said. "Today the company not only has some
of the most efficacious aloe-based products on the market but also
some of the industry's most innovative multivitamin, multimineral and
antioxidant nutritional products."
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high quality
nutritional supplements and personal care products to a growing
population of consumers seeking wellness and a healthy lifestyle.
Under its MPM Medical brand, RBC Life Sciences also develops and
markets to health care professionals in the United States proprietary
prescription and nonprescription products for advanced wound care and
pain management. All products are tested for quality assurance
in-house, and by outside independent laboratories, to comply with
regulations in the U.S. and in more than thirty countries in which the
products are distributed. For more information, visit the Company's
Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact,
may be forward-looking. Actual events will be dependent upon a number
of factors and risks including, but not limited to, changes in plans
by the Company's management, delays or problems in production, changes
in the regulatory process, changes in market trends, and a number of
other factors and risks described from time to time in the Company's
filings with the Securities and Exchange Commission.
Van Zelfden Communications
Alan Van Zelfden, 469-964-0216
alan.vanzelfden@rbclifesciences.com
or
RBC Life Sciences
Ann Billings, 972-893-4000
ann.billings@rbclifesciences.com
Keyword: United States North America Texas
Industry Keyword: Health Fitness & Nutrition Pharmaceutical Survey Product/Servi
e Retail Food/Beverage Other Retail
Source: RBC Life Sciences
*** end of story ***
I've done a lot of the iBox update. I'm probably forgetting something so I'll come back later and make updates for anything I forgot.
Mike
Recently I've been loading RBCL heavily. I think with the huge backlog growth they have a good chance of being a double by the end of the year. I'm working on updating the iBox and will post when it is finished.
Mike
mike, wonder whats up with the selling. Market sucks or someone that knows something. I saw the move down to .45, but didn't place an order to buy. I don't have a ton of this stuff so I could have added, guess I'm just gun shy. Earnings won't be out for a while.
Tough market in the micros.
And a belated congrats to the your newest family micro.
It is pretty amazing to almost double their backlog.
Mike
Huge backlog increase. I bought a few more today. Its a bet that at some point - hopefully next qtr, they will convert that backlog into a big quarter. Earnings did underwhelm.
Best.
RBC Life Sciences Reports Second Quarter Results
Tuesday August 5, 11:31 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences, Inc. (OTCBB: RBCL - News) today reported net sales of $6.89 million for the quarter ended June 30, 2008 compared to net sales of $7.15 million for the same period last year. The Company’s net earnings in the second quarter of 2008 were $276,000, or $0.01 per diluted share, compared to net earnings of $510,000, or $0.02 per diluted share, in the second quarter of 2007.
The Company also reported a six percent increase in net sales to $13.23 million for the first six months of 2008 compared to net sales of $12.54 million in the same period last year. The Company’s net earnings were $631,000, or $0.03 per share, in the first six months of this year compared to net earnings of $835,000, or $0.04 per share, in the same period last year.
Clinton Howard, CEO of RBC Life Sciences, said, “Sales of Medical Products continued to grow during the second quarter of 2008, increasing 32 percent over the same period last year. Second quarter sales included our first shipments of Medical Products to Brazil under the exclusive distribution agreement we completed in March of this year.
“Second quarter results were negatively affected by a delay in planned shipments to certain international licensees. We were pleased to see shipping activity begin to return to anticipated levels during June and July as our licensees increased shipments of our products into major international markets.”
Backlog associated with international orders increased to $11.2 million at June 30, 2008 compared to $6.1 million at March 31, 2008 and $6.4 million at June 30, 2007.
Mr. Howard continued, “Our results were also affected by certain noteworthy expenses incurred during the second quarter. In June we sponsored a major event for our North American Associates to provide training and motivation and to introduce them to our newest marketing initiatives. This event represented a significant investment in our Associate base as part of our overall strategy to increase sales and new Associate recruiting. Also during the quarter, we encountered expenses associated with the completion of the major improvement and repair project on our headquarters’ building.”
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC also develops and markets to health care professionals proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company’s Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
RBC Life Sciences, Inc.
Summary Results of Operations
(in thousands, except per share data)
(unaudited)
Quarters Ended June 30,
2008 2007
Net sales $ 6,887 $ 7,148
Gross profit 3,697 3,793
Operating profit 501 866
Earnings before income taxes 456 812
Provision for income taxes 180 302
Net earnings 276 510
Earnings per share
Basic $ 0.01 $ 0.03
Diluted $ 0.01 $ 0.02
Weighted average shares outstanding – basic 21,243 20,266
Weighted average shares outstanding – diluted 22,944 21,499
Six Months Ended June 30,
2008 2007
Net sales $ 13,234 $ 12,540
Gross profit 7,199 7,098
Operating profit 1,112 1,458
Earnings before income taxes 1,023 1,345
Provision for income taxes 392 510
Net earnings 631 835
Earnings per share – basic and diluted $ 0.03 $ 0.04
Weighted average shares outstanding – basic 21,179 20,227
Weighted average shares outstanding – diluted 22,920 22,109
RBC Life Sciences, Inc.
Condensed Balance Sheets
(in thousands)
(unaudited)
June 30, December 31,
2008 2007
Assets
Cash and cash equivalents $ 5,373 $ 6,369
Inventories 5,702 4,725
Other current assets 1,857 1,334
Total current assets 12,932 12,428
Other assets 6,803 6,730
Total assets $ 19,735 $ 19,158
Liabilities and shareholders’ equity
Accounts payable and accrued liabilities $ 2,982 $ 4,431
Deferred revenue 5,736 4,323
Other current liabilities 139 136
Total current liabilities 8,857 8,890
Other liabilities 2,568 2,690
Shareholders’ equity 8,310 7,578
Total liabilities and shareholders’ equity $ 19,735 $ 19,158
Here is the updated backlog information for CCI their principal licensee. Backlog was up huge in Q2. Q3 should be a monster report.
Quarter Backlog
Q2'08 $11,200,000
Q1'08 $6,081,000
Q4'07 $5,778,000
Q3'07 $5,828,000
Q2'07 $6,369,000
Q1'07 $5,343,000
Q4'06 $3,374,000
Q3'06 $2,718,000
Q2'06 $3,469,000
Q1'06 $3,091,000
Q4'05 $2,436,000
Mike
RBC Life Sciences Holds National Summit
Tuesday June 17, 9:25 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences Inc. (OTCBB: RBCL - News) held a very successful North American Summit in Dallas, Texas June 6 – 7. The Company’s Independent Associates converged on the Embassy Suites Outdoor World to hear from RBC executives, peers and field leaders about new products being offered to the market place. Among the products discussed was OliViva. OliViva is RBC’s new functional beverage made from a proprietary blend of fresh olive leaf complex and six other legendary botanicals. It has the antioxidant power of six servings of fruits and vegetables in just one ounce.
The North American Summit attracted record attendance and was the Company’s largest event in a number of years, with Associates from across North America. “The success of the event is a key indicator that we are on the right track in our market. Our Associates expressed overwhelming support and enthusiasm for the new products, including the newly introduced Spirulina Whole Food Bar,” said John Price, President of RBC. “Our foundation is whole food and natural nutrition, manufactured to our strict guidelines, using our proprietary ingredients and adhering to Good Manufacturing Practices (GMP).”
“The Summit afforded us the opportunity to launch the new Spirulina bars to a group of product consumers who demand the very best, and they got it,” stated Kevin Young, Director of Sales. From the early days of Spirulina’s introduction to the market by Dr. Christopher Hills, to today’s launch of the Whole Food Bar, RBC has worked to keep “nature’s most complete food” a viable, affordable supplement to the consuming public. The bars will go on sale in early July.
Additionally, RBC will convene for a National Training Weekend during October 2008, in Los Angeles, California. Associates will be educated and trained on how to use the Company’s products in their healthy lifestyles and how to share the benefits with others.
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.
Contact:
Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
gdebusk@halliburtonir.com
or
Deidra Roy, 972-458-8000
droy@halliburtonir.com
or
Chase Zavoina, 972-458-8000
czavoina@halliburtonir.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences Inc.
RBC Life Sciences Opens Training Center in Los Angeles
Monday June 2, 7:00 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences (OTC BB: RBCL - News) hosted a successful grand opening of its Los Angeles training center on Saturday, May 24. This unique center is open to all RBC Independent Associates and provides Southern California representatives with direct access to RBC products, networking opportunities and training. RBC Associates and their guests who attended the grand opening of the new office had the opportunity to network and learn more about RBC’s business and its products.
“Education and training are the cornerstones of our business,” stated Director of Sales Kevin Young. “This new facility will serve our associates well and will give RBC a valuable presence in what is already a very strong market for us.”
The Los Angeles office is located on Wilshire Boulevard, which is accessible and convenient to the entire Southern California area. This is RBC’s first training center in the United States, and management believes the center has great potential for the company.
“The success of this facility will assist RBC in determining future training center locations,” said President John Price. “RBC received a great deal of support from the local community, and we were impressed with the community’s strong commitment to health and nutrition.”
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
Contact:
Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
gdebusk@halliburtonir.com
or
Deidra Roy, 972-458-8000
droy@halliburtonir.com
or
Chase Zavoina, 972-458-8000
czavoina@halliburtonir.com
--------------------------------------------------------------------------------
Source: RBC Life Sciences
Reduction of Pain, Itching, and Rash Shown in Study of Oncology Patients by MPM Medical, Inc., Subsidiary of RBC Life Sciences
Thursday May 29, 7:00 am ET
IRVING, Texas--(BUSINESS WIRE)--MPM Medical, Inc., today announced that a peer-reviewed clinical research study of its proprietary product Regenecare® showed effective reduction in severe burning, itching, and rashes, adverse side effects suffered by patients treated with frequently used anti-cancer drugs known as EGFR (Epidermal Growth Factor Receptor) inhibitors. The study was presented at the 33rd Annual Oncology Nursing Society Congress held in Philadelphia, PA this past weekend and attended by approximately 5,000 oncology nurses.
Paul R. Miller, President of MPM Medical, stated, “Over 85% of patients treated with EGFR inhibitors develop red rashes which can cause such pain and embarrassment that some patients stop the treatment. In the past, products to relieve these skin conditions have not been available. We are pleased to be able to show oncology nurse specialists from across the country that their patients don’t have to live with the pain caused by EGFR anti-cancer treatment.”
MPM Medical, Inc., a wholly-owned subsidiary of RBC Life Sciences, Inc. (OTCBB: RBCL - News), develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.
The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
Contact:
Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
gdebusk@halliburtonir.com
or
Chase Zavoina, 972-458-8000
czavoina@halliburtonir.com
or
Deidra Roy, 972-458-8000
droy@halliburtonir.com
--------------------------------------------------------------------------------
Source: MPM Medical, Inc.
Here is the updated backlog information for CCI their principal licensee. Backlog was up nicely in Q1 which bodes well for the Q2 report.
Quarter Backlog
Q1'08 $6,081,000
Q4'07 $5,778,000
Q3'07 $5,828,000
Q2'07 $6,369,000
Q1'07 $5,343,000
Q4'06 $3,374,000
Q3'06 $2,718,000
Q2'06 $3,469,000
Q1'06 $3,091,000
Q4'05 $2,436,000
The RBCL numbers were decent but not great. I was hoping for earnings north of $0.02/share but am happy with $0.016/share. I like the long term trend for the company and will continue to hold them. I'm looking forward to the 10-Q so that I can do some more analysis.
Mike
What are your feelings about these numbers Mike?
RBC Life Sciences Reports 18 Percent Higher Revenues in the First Quarter of 2008
Monday May 5, 10:35 am ET
IRVING, Texas--(BUSINESS WIRE)--RBC Life Sciences, Inc. (OTCBB: RBCL - News) today announced that net sales for the first quarter ended March 31, 2008, increased 18 percent to $6.35 million, compared to net sales of $5.39 million for the quarter ended March 31, 2007. The Company’s net earnings for the first quarter of 2008 improved 9 percent to $355,000, or $0.02 per share, compared to net earnings of $325,000, or $0.02 per share, in the first quarter of 2007. Diluted shares outstanding for the 2008 quarter were 22,573,000, compared to 21,557,000 for the first quarter of 2007.
“We are pleased with RBC’s continued growth in the first quarter,” said Clinton Howard, Chairman and CEO. “Our Nutritional Products segment grew more than 14% compared to last year’s first quarter, due primarily to an increase in revenues from our international licensees. Our Medical Products group showed 32% growth quarter over quarter, due to an increase in the customer base for our wound care products and increased sales to our largest customer in this segment. We look forward to continued growth from each of our segments in 2008.”
RBC Life Sciences develops, manufactures and markets high quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company’s Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
RBC Life Sciences, Inc.
Summary Results of Operations
(in thousands, except per share data)
(unaudited)
Quarters Ended March 31,
2008 2007
Net sales $ 6,348 $ 5,392
Gross profit 3,503 3,304
Operating profit 612 592
Earnings before income taxes 567 533
Provision for income taxes 212 208
Net earnings 355 325
Earnings per share – basic and diluted $ 0.02 $ 0.02
Weighted average shares outstanding – basic 21,114 20,188
Weighted average shares outstanding – diluted 22,573 21,557
RBC Life Sciences, Inc.
Condensed Balance Sheets
(in thousands)
(unaudited)
March 31, December 31,
2008 2007
Assets
Cash and cash equivalents $ 5,730 $ 6,369
Inventories 4,946 4,725
Other current assets 1,092 1,334
Total current assets 11,768 12,428
Other assets 6,704 6,730
Total assets $ 18,472 $ 19,158
Liabilities and shareholders’ equity
Accounts payable and accrued liabilities $ 3,025 $ 4,431
Deferred revenue 4,687 4,323
Other current liabilities 136 136
Total current liabilities 7,848 8,890
Other liabilities 2,629 2,690
Shareholders’ equity 7,995 7,578
Total liabilities and shareholders’ equity $ 18,472 $ 19,158
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
180
|
Created
|
07/22/07
|
Type
|
Free
|
Moderators |
Overview
RBC Life Sciences, Inc., together with its subsidiaries, engages in the marketing and distribution of nutritional supplements and personal care products in the United States, Canada, South Korea, and Japan. It operates in two segments, Nutritional Products and Medical Products. The Nutritional Products segment offers a line of approximately 75 nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life Sciences brand. It markets these products in four categories: wellness products, weight loss products, fitness products, and skin care products. This segment markets its products through a network of independent distributors, as well as through licensing arrangements with third parties. The Medical Products segment markets a line of approximately 28 wound care and oncology products under the MPM Medical brand throughout the United States. The wound care products are for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. These products include wound and skin cleansers, wound dressings, a moisture barrier cream, and hydrogel wound dressing with Lidocaine. The oncology products are designed to reduce destruction to skin and tissue caused by radiation, and to reduce pain and itching caused by radiation reactions in the skin and the internal mucosa. This segment distributes these products to hospitals, nursing homes, clinics, and pharmacies through medical/surgical supply dealers and pharmaceutical distributors.
Web Sites
http://www.rbclifesciences.com
http://www.mpmmedicalinc.com
Sample Products
Investment Thesis
1. Rapidly Growing Earnings - RBCL had record EPS of $0.037 in Q3, the most recent quarter. Given their backlog, 2008 likely will produce record annual earnings. 2007 earnings were a huge improvement over 2006 ($0.08 in 2007 vs. $0.02 in 2006). They have a very strong trend of improvement in earnings over a long period of time and I expect that trend to continue.
2. Huge Backlog - Backlog is $8.7M for their CCI account in the most recent quarter which is the second highest level in history. Also, the backlog only represents a portion of their sales going forward. They have GM of 47.5% so additional sales drop rapidly to the bottom line.
3. Rapidly Growing Medical Sales - Medical sales jumped 42% year-over-year and looks like it will continue. At the end of March they announced an expansion of their medical segment into Latin America. They also announce in February that they would begin selling their products in Kroger. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=28065107 http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26926765
4. Expanding Nutritional Sales - Nutritional sales increased 23.5% in the most recent quarter due to international expansion. The company has embarked on some new initiatives to expand their US and Canadian nutritional sales.
5. Strong Balance Sheet - RBCL has a book value of $0.44 which includes $0.23 in cash. That puts them in a strong position financially to continue growing.
6. Recession Resistant Business - Their business is recession resistant which is a strong plus in this economic environment.
Historical Financial Information
Quarter | Revenue | Diluted EPS |
Q3'09 | $6.49M | -$0.007 |
Q2'09 | $6.76M | $0.012 |
Q1'09 | $6.02M | -$0.008 |
Q4'08 | $7.25M | * $0.006 |
Q3'08 | $9.93M | $0.037 |
Q2'08 | $6.89M | + $0.012 |
Q1'08 | $6.35M | $0.016 |
Q4'07 | $6.63M | x $0.008 |
Q3'07 | $7.86M | $0.029 |
Q2'07 | $7.15M | $0.023 |
Q1'07 | $5.39M | $0.015 |
Q4'06 | $5.28M | $0.005 |
Q3'06 | $5.40M | $0.004 |
Q2'06 | $6.20M | $0.013 |
Q1'06 | $4.81M | -$0.002 |
Q4'05 | $4.95M | $0.003 |
Q3'05 | $4.91M | $0.007 |
Q2'05 | $5.36M | $0.018 |
Q1'05 | $4.14M | -$0.000 |
Q4'04 | $5.24M | $0.014 |
Q3'04 | $4.07M | $0.001 |
Q2'04 | $4.72M | $0.007 |
Q1'04 | $4.24M | $0.004 |
* Q4'08 results had unusually high tax at 55.2% vs. 39.6% for the entire year. If the average tax rate had applied they would have had EPS of $0.008.
+ Q2'08 EPS was impacted by some one-time items. They incurred expenses for an event to train/motivate their sales associates and also had expenses for renovations on their headquarters' building. They
didn't quantify the costs for these one time items but certainly EPS would have been higher without them. I suspect the EPS impact was on the order of $0.008/share. Also they had some shipping delays
that impacted Q2. Without these one-time items the Q2 report would have been much better.
x Without a one-time write-off they would have made $0.023/share. See the following post for details:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=27753484
Earnings Reports
Q4'08 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35859247
Q3'08 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=33448261
Q2'08 - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=31228787
Q1'08 - http://investorshub.advfn.com/boards/read_msg.asp?message_id=29030527
Q4'07 - http://investorshub.advfn.com/boards/read_msg.asp?message_id=27391526
Q3'07 - http://investorshub.advfn.com/boards/read_msg.asp?message_id=25632255
Backlog Information
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=33513933
Charts
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |